docetaxel anhydrous has been researched along with Hypokalemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Beijnen, JH; de Weger, VA; Huitema, ADR; Janssen, JM; Keessen, M; Lopez-Yurda, MI; Marchetti, S; Rosing, H; Thijssen, B; Vermunt, MAC | 1 |
| Bacay, A; Bakst, RL; Catalano, PJ; Chau, NG; Gupta, V; Haddad, RI; Hanna, GJ; Mahmood, U; Margalit, DN; McHugh, P; Misiukiewicz, KJ; Posner, M; Rabinowits, G; Rath, L; Rawal, B; Schoenfeld, JD; Tishler, RB | 1 |
| Chi, KN; Fizazi, K; Haqq, CM; Higano, CS; Kheoh, T; Li, J; Marberger, M; Molina, A; Mulders, PF; Saad, F | 1 |
3 trial(s) available for docetaxel anhydrous and Hypokalemia
| Article | Year |
|---|---|
Effect of Food on the Pharmacokinetics of the Oral Docetaxel Tablet Formulation ModraDoc006 Combined with Ritonavir (ModraDoc006/r) in Patients with Advanced Solid Tumours.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Diet, High-Fat; Docetaxel; Drug Combinations; Fasting; Fatigue; Female; Food-Drug Interactions; Humans; Hypokalemia; Male; Middle Aged; Neoplasms; Ritonavir; Tablets; Therapeutic Equivalency | 2021 |
A Phase 1 Study of Afatinib in Combination with Postoperative Radiation Therapy with and Without Weekly Docetaxel in Intermediate- and High-Risk Patients with Resected Squamous Cell Carcinoma of the Head and Neck.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Head and Neck Neoplasms; Humans; Hypokalemia; Male; Maximum Tolerated Dose; Middle Aged; Mouth Neoplasms; Mucositis; Postoperative Period; Prospective Studies; Radiotherapy Dosage | 2019 |
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Topics: Abiraterone Acetate; Adult; Age Factors; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Fatigue; Humans; Hypertension; Hypokalemia; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids | 2014 |